Mexico Gastrointestinal Therapeutics Market Size & Outlook
Mexico gastrointestinal therapeutics market, 2018-2030 (US$M)
Related Markets
Mexico gastrointestinal therapeutics market highlights
- The Mexico gastrointestinal therapeutics market generated a revenue of USD 468.1 million in 2022 and is expected to reach USD 607.9 million by 2030.
- The Mexico market is expected to grow at a CAGR of 3.3% from 2023 to 2030.
- In terms of segment, branded was the largest revenue generating drug type in 2022.
- Generics is the most lucrative drug type segment registering the fastest growth during the forecast period.
Gastrointestinal therapeutics market data book summary
| Market revenue in 2022 | USD 468.1 million |
| Market revenue in 2030 | USD 607.9 million |
| Growth rate | 3.3% (CAGR from 2022 to 2030) |
| Largest segment | Branded |
| Fastest growing segment | Generics |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Branded, Generics |
| Key market players worldwide | AbbVie Inc, AstraZeneca PLC, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Bayer AG, Abbott Laboratories, Janssen Pharmaceuticals, Sun Pharmaceutical Industries, Cipla Ltd DR, Gilead Sciences Inc, Biogen Inc, Organon & Co Ordinary Shares |
Other key industry trends
- In terms of revenue, Mexico accounted for 1.2% of the global gastrointestinal therapeutics market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil gastrointestinal therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- Argentina is the fastest growing regional market in Latin America and is projected to reach USD 252.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Gastrointestinal Therapeutics Market Scope
Gastrointestinal Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Mexico gastrointestinal therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gastrointestinal therapeutics market will help companies and investors design strategic landscapes.
Branded was the largest segment with a revenue share of 62.14% in 2022. Horizon Databook has segmented the Mexico gastrointestinal therapeutics market based on branded, generics covering the revenue growth of each sub-segment from 2018 to 2030.
High prevalence of GI disorders in Mexico is anticipated to fuel demand for gastroenterological therapeutics and aid its growth over in coming years. In addition, according to Revista de Gastroenterología de México (Mexican Journal of Gastroenterology), in December 2016, the prevalence of GERD was significantly high in Mexico, with regurgitation as the major symptom, followed by heartburn.
Reasons to subscribe to Mexico gastrointestinal therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Mexico gastrointestinal therapeutics market databook
-
Our clientele includes a mix of gastrointestinal therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico gastrointestinal therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Mexico gastrointestinal therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Mexico gastrointestinal therapeutics market size, by drug type, 2018-2030 (US$M)
Mexico Gastrointestinal Therapeutics Market Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
